KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arbutus Biopharma (ABUS) EBIT Margin (2016 - 2025)

Arbutus Biopharma (ABUS) has disclosed EBIT Margin for 13 consecutive years, with 503.33% as the latest value for Q4 2025.

  • Quarterly EBIT Margin rose 38187.0% to 503.33% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 270.96% through Dec 2025, up 96577.0% year-over-year, with the annual reading at 270.96% for FY2025, 96577.0% up from the prior year.
  • EBIT Margin hit 503.33% in Q4 2025 for Arbutus Biopharma, up from 1636.86% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 13.86% in Q2 2025 to a low of 1636.86% in Q3 2025.
  • Historically, EBIT Margin has averaged 712.93% across 5 years, with a median of 599.9% in 2021.
  • Biggest five-year swings in EBIT Margin: crashed -113838bps in 2024 and later skyrocketed 126432bps in 2025.
  • Year by year, EBIT Margin stood at 648.66% in 2021, then soared by 44bps to 361.28% in 2022, then plummeted by -168bps to 967.23% in 2023, then rose by 8bps to 885.2% in 2024, then surged by 43bps to 503.33% in 2025.
  • Business Quant data shows EBIT Margin for ABUS at 503.33% in Q4 2025, 1636.86% in Q3 2025, and 13.86% in Q2 2025.